NIH sued by Boston biolab foes

Group claims agency violated federal law in choosing densely populated site for new biocontainment facility

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
An activist legal group filed suit against the National Institutes of Health (NIH) Thursday (May 18), claiming the agency's decision to approve building a high-security biocontainment lab in a densely populated, largely minority community around Boston's South End violates federal law.The suit, filed in U.S. District Court in Boston by the Conservation Law Foundation on behalf of five black and Puerto Rican residents, claims NIH broke the National Environmental Policy Act (NEPA) by not conducting a thorough environmental review of the site, not "taking a comprehensive, objective look at the environmental risks" to nearby residents, and not considering alternative sites. The suit claims the neighborhood meets the federal definition of an "environmental justice community," one where minority residents are overburdened by environmental hazards. It asks the court to stop all federal funding of the biolab.The biolab, called the National Emerging Infectious Diseases Laboratory, has been controversial since September 2003, when the NIH's National Institute for Allergy and Infectious Disease chose Boston over other competing cities. The $178 million lab, consisting of biosafety levels (BSL) 2, 3, and 4, would be one of only a dozen labs in the country authorized to conduct research on incurable fatal diseases such as Ebola virus. In April 2004, 146 Massachusetts university professors sent a letter to Boston's mayor and BU's trustees, saying that the risk of human error or terrorist attacks was too great to accept.However, in February, NIH awarded Boston University (BU) $128 million to build the lab. Preliminary site work began last month, according to a BU spokeswoman, but no excavation has taken place and nothing has been built. Eloise Lawrence, staff attorney for the Conservation Law Foundation and lead lawyer for the plaintiffs, told The Scientist residents were scared to live near a facility where samples of fatal, non-curable diseases were transported into and out of the lab by commercial carriers driving through local streets.A spokesman for the Department of Health and Human Services declined to comment on the lawsuit, as did BU's spokeswoman. Yesterday, lab director Mark Klempner, BU medical center's associate provost, said in a statement that NIH's environmental assessment was totally above board. "The approval process for the laboratory was rigorous and thorough and Boston University Medical Center complied fully with all federal, state and local processes and procedures."jmiller@the-scientist.comLinks within this article"Activists sue NIH, claim BU biolab funding illegal," Conservation Law Foundation, May 18, 2006. http://www.clf.org/general/internal.asp?id=857J.D. Miller, "NIH OKs embattled Boston biolab," The Scientist, February 3, 2006. http://www.the-scientist.com/news/display/23076/Conservation Law Foundation http://www.clf.org/National Environmental Policy Act of 1969 http://ceq.eh.doe.gov/Nepa/regs/nepa/nepaeqia.htm"Stop the Bioterrorism Lab," Alternatives in Community and Environment. http://www.ace-ej.org/BiolabWeb/biolab.htmlJ.D. Miller, "Sparks fly on Boston lab plan," The Scientist, May 5, 2004. http://www.the-scientist.com/article/display/22154/
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • John Dudley Miller

    This person does not yet have a bio.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Discover a serum-free way to produce dendritic cells and macrophages for cell therapy applications.

Optimizing In Vitro Production of Monocyte-Derived Dendritic Cells and Macrophages

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with Lipid Nanoparticles

Thermo Fisher Logo